Pipeline

Micellar Nanoparticles: Clinical Pipeline

Product BR PC phaseⅠ phaseⅡ phaseⅢ
NC-6004
Cisplatin micelle
Head and Neck cancer(USA/EU/Taiwan)
Combination therapy with Kyet ruda®
Co-Development
Partner:Orient Europharma(Taiwan)
NC-6300
Epirubicin micelle
Soft tissue sarcoma(USA)
In-House Development
FDA Orphan drug designation
SRN-14/GL2-800
(PRDM14 siRNA)
HER2-negative breast cancer (Japan)
Investigator-initiated
NK105
Paclitaxel micelle
(Out-Licensed)
Breast cancer(Japan/Asia)
Out-licensed to Nippon Kayaku(Aria:Japan/Asia)

In-licensing Pipeline

Product BR PC phaseⅠ phaseⅡ phaseⅢ Marketing
VB-111
Non-replicating Adeno 5 vector
Ovarian cancer(Decided to participate)
In-House Development
In-Licensed from VBL(Aria:Japan)
Partner:VBL(Israel)
Ovarian cancer
Operation byVBL(USA etc.)
rGBM
Investigator-initiated(USA)
Colorectal Cancer
Operation by NCI/VBL(USA)
ENT103
ENT product
Otitis media(Japan)
Co-Development
Partner:CEOLIA PHARMA(Japan)
Aeon Acti-PRP
Regenerative medicine
Intractable infertility PRP therapy(Japan)
Distributor